48
Screening for COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

S creening for COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

  • Upload
    iman

  • View
    22

  • Download
    1

Embed Size (px)

DESCRIPTION

S creening for COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis. THE WHO DEFINITION OF HEALTH. Health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity. What is screening?. - PowerPoint PPT Presentation

Citation preview

Page 1: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

Screening for COPD IN PHCWORKSHOP

Vasiliki Garmiri

Athanasios Symeonidis

Page 2: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

THE WHO DEFINITION OF HEALTH

• Health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity.

Page 3: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

What is screening?

• “Screening is the presumptive identification of unrecognized diseases or defects by the application of tests, examinations or other procedures which can be applied rapidly.”

• “Screening tests sort out apparently well persons who probably have a disease from those who probably do not.”

The CCI Conference on Preventive Aspects of Chronic Disease, 1951

Page 4: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

• A screening test is not intended to be diagnostic.

• Persons with positive or suspicious findings must be referred to their physicians for diagnosis and necessary treatment.

The CCI Conference on Preventive Aspects of Chronic Disease, 1951

Page 5: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

Why SCREENING?

• Because a plethora of medical conditions have no apparent symptoms.

• Because it is important to know the incidence, prevalence and natural course of disease.

Page 6: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

Principles of early disease detection – prerequisites

1. An important health problem

2. A recognizable early symptomatic/latent stage

3. Available facilities for diagnosis

4. Accepted treatment for persons with the condition AND an agreed policy on whom to treat as patients (*)

5. Suitable screening test/examination (valid, reliable, easy, quick, with an acceptable yield)

Page 7: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

6. An acceptable test

7. The economically balanced cost of screening and case finding

8. A clear understanding of the natural history of the condition

9. Casefinding should be a continuing process

Principles of early disease detection – prerequisites

Page 8: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

• CASE FINDING (and treatment)

• SURVEYS (POPULATION/ EPIDEMIOLOGICAL) (prevalence, incidence, the natural history of the disease)

• EARLY DISEASE DETECTION (secondary prevention)

What are the aims of Screening?

Page 9: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

Screening Methodology

• Physical examination by a medical practitioner

• Lab tests

• Medical history

• Questionnaires

Page 10: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

The primary health care approach:

• Equity

• Universal coverage with basic services

• Multisectoral approach

• Community involvement

• Health promotion

Page 11: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

• Access to the majority of the population

• Regarded as a credible source of lifestyle advice, it improves population levels of lifestyle risk factors

• Health promotion + disease prevention is a key component of the role of GPs

• The unique doctor-patient relationship

Why PRIMARY CARE?

Page 12: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

Why PRIMARY HEALTH CARE?

• The point of first contact – it provides continuing care and a holistic approach.

• GPs can guide their patients according to their findings.

• GPs are familiar with the lifestyle modification approach.

Page 13: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

• It is oriented towards the needs of the patient AND the community.

• The Primary Health Care doctor engages in organized activities outside the office (alone/PHC team).

Why PRIMARY HEALTH CARE?

Page 14: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

THE OTTAWA CHARTER FOR HEALTH PROMOTION, WHO,1986. THE ROLE OF GPs IN HEALTH PROMOTION

• Advocating for health

• Enabling people to achieve their fullest health potential

• Mediating with government and nongovernment agencies, industry and the media

Page 15: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

THE OTTAWA CHARTER FOR HEALTH PROMOTION, WHO, 1986. FIVE PRINCIPLES/STRATEGIES

1. Build healthy public policy

2. Create supportive environments

3. Strengthen community actions

4. Develop personal skills

5. Reorient health services

Page 16: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

SCREENING FOR COPD IN PRIMARY HEALTH CARE

Page 17: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

COPD – Statistics

• It is difficult to assess the burden of COPD (the large gap between the prevalence described as airflow limitation and clinically significant disease).

• The most appropriate criteria for different settings are still a matter of discussion.

• Still, morbidity and mortality are significant.

GOLD

REPORT,2009

Page 18: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

Estimates of prevalence

• A doctor’s self-report concerning COPD diagnosis

• Spirometry with/without a bronchodilator

• Questionnaires about respiratory symptoms

Page 19: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

• Screening for COPD is quick, easy, not interventional and it can be done in PHC.

• Early diagnosis and treatment can change the natural course of disease.

• Smoking cessation intervention is an important preventive and health promotion measure in PHC.

Why COPD?

Page 20: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

COPD screening

• Community-based spirometric screening still of unclear benefit (the GOLD report, 2009)

• High-risk group: Males > 40, smokers and ex-smokers

Page 21: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

• “In a multivariate analysis, age, BMI, smoking status and pack-years, symptoms (cough, phlegm, dyspnoea, wheeze) and prior diagnosis consistent with asthma or COPD all showed a significant ability to discriminate between persons with and without obstruction in the general population.”

van Schayck CP, Halbert RJ, Nordyke RJ et al. Comparison of existing symptom-based questionnaires for identifying COPD in the general practice setting. Respirology 2005; 10: 323-333

CAN I DISCRIMINATE THROUGH SYMPTOMS?

Page 22: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

What do I need to access in PHC?

• Tobacco use• Pulmonary function• Patient questionnaires• Number of exacerbations• Exercise (?)

Page 23: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

Who should be screened with spirometry?

• Smokers > 35(*)• Patients with symptoms suggestive of COPD• Patients testing positive on a risk evaluation

questionnaire (COPD/IPCRG COPD)• *Patients ≥ 30 at high-risk (e.g. a family history of COPD,

occupational or environmental risk, a smoker since childhood)

Spirometry in primary care case-identification, diagnosis and management of COPD.David Price, Alan Crockett, Mats Arne, Bernard Garbe, Rupert Jones, Alan Kaplan, Arnulf Langhammer, Siân Williams, Barbara Yawn.

Page 24: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

Who should be referred for diagnostic spirometry?

• FEV1 < 80% predicted

or

• FEV1/FVC < 0.8 (80%)

or

• FEV1/FEV6 < 0.8 (80%)

Spirometry in primary care case-identification, diagnosis and management of COPD.David Price, Alan Crockett, Mats Arne, Bernard Garbe, Rupert Jones, Alan Kaplan, Arnulf Langhammer, Siân Williams, Barbara Yawn.

Page 25: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

COPD – Risk factors

• Genes

• Exposure to particles– Tobacco smoke– Occupational dusts, organic and inorganic– Indoor air pollution from heating and cooking

with biomass in poorly vented dwellings– Outdoor air pollution

Page 26: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

COPD – Risk factors• Lung growth and development• Oxidative stress• Gender• Age• Respiratory infections• A previous case of tuberculosis• Socioeconomic status• Nutrition• Comorbidities (Asthma)

Page 27: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

REMEMBER!

• Everyone should be asked about present or past tobacco use.

• Health promotion should be directed toward everyone.

Page 28: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

PART III

• TIME TO WORK IN GROUPS OF THREE!

Page 29: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

CASE

• Patient, 50 years old, thin• Wants a lab. check-up “as a result of pressure

from his/her spouse,” “otherwise he/she wouldn’t bother, there’s nothing wrong with me”

• Occasionally measures bp – always around 120/80 mmHg

Page 30: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

• Paying attention to international guidelines, you ask about tobacco use.

• The patient is a smoker.

CASE

Page 31: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

DOCTORS

• You have five minutes to talk to the patient and make a smoking cessation intervention.

Page 32: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

PATIENTS

• After you have heard your doctor you have three minutes to tell him:

1.How you felt

2.Whatever you would like to point out (e.g. What you would like to hear, how you would have

preferred to be approached, how you might be motivated, etc.)

Page 33: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

OBSERVERS – TO THE GROUP

• Each observer will have one min. to focus briefly (a few words) on the following:

1.What was particularly good about the consultation.

2.The main aspect that would need improvement or was not mentioned.

3.The most interesting thing the patient said.

Page 34: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

TOBACCO USE – STATISTICS

• Tobacco use is a major cause of lung cancer, CVD, and COPD.

• Tobacco use causes 1 200 000 deaths each year in WHO's European region (14% of all deaths).

• Unless more is done to help the 200 million European adult smokers stop smoking, the result will grow to 2 million European deaths from smoking a year by 2020.

http://tobaccocontrol.bmj.com/content/11/1/44.full

Page 35: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

The European Commission published a survey on the smoking of 26 500 Europeans which took place in 28 countries (EU 27 and Norway) in December 2008.

2008 EUROBAROMETER SURVEY ON TOBACCOSUMMARY REPORT

3/10 EU citizens ≥ 15y say they smoke: 26% smoke daily, 5% occasionally, 22% of citizens say they have quit smoking.

Almost half of EU citizens claim that they have never smoked.

The proportion of smokers is the highest in Greece (42%), followed by Bulgaria (39%), Latvia (37%), Romania, Hungary, Lithuania, the Czech Republic and Slovakia (all 36%).

Page 36: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

The European tobacco control report 2007

• A fall in death rates from lung cancer among men across the Region.

• Rates among women are still increasing. • Among young people, around 25% of 15-year-olds smoke every

week and there has been no significant change in this level in recent years.

• The prevalence of smoking among 15-year-old girls in many western European countries exceeds that among 15-year-old boys, while the reverse is true in eastern Europe.

Page 37: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

THE FIVE “A”sBrief strategies to help patients willing to quit smoking

• ASK

• ASSESS

• ADVISE

• ASSIST

• ARRANGE

Page 38: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

THE FIVE “R”sProviding motivational interventions to patients unwilling to quit

• RELEVANCE

• RISKS

• REWARDS

• ROADBLOCKS

• REPETITION

Page 39: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

A few key points to cover in a few minutes

• Set a stop day and stop completely on that day.• Review past experiences and learn from them.• Make a personalized action plan.• Identify likely problems + plan on how to cope with them.• Ask family and friends for support.

Page 40: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

Prevent relapse!!!1. Open-ended questions

2. Active discussion

3. Help patients identify coping mechanisms to address threats

DON’T FORGET TO…

Page 41: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

DON’T FORGET…

• The young

• Ex-smokers

• Secondhand smokers

Page 42: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

Top 5 secondary losses when someone quits smoking

• Friends• Feelings of loneliness• Low self-esteem• Boredom• Indulgence

Page 43: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

Recommendations for smoking cessation specialists – Intensive Support

Treatment as back-up to brief opportunistic interventions.

• Individually/in groups• Coping skills training + social support• Around five one-hour sessions over approx. one month + follow up• NRT/bupropion/varenicline as appropriate

Page 44: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

PHARMACOTHERAPY

• Bupropion and varenikline• NRT products: the patch, gum, nasal sprays, inhalators, tablets,

lozenges

Smokers of 10 or more cigarettes a day who are ready to stop should be encouraged to use NRT or bupropion/varenikline as a cessation aid.

Page 45: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

References• Wilson JMG, Jungner G. Principles and practice of screening for disease. WHO,

Public Health Papers No. 34. Geneva: WHO, 1968• Braveman PA, Tarimo E. Screening in primary health care. Setting priorities with

limited resourses. Geneva: WHO, 1994• Price DB, Tinkelman DG, Halbert RJ et al. Symptom-based questionnaire for

identifying COPD in smokers. Respiration 2006; 73: 285-295• Tinkelman DG, Price DB, Nordyke RJ et al. Symptom-based questionnaire for

differentiating COPD and asthma. Respiration 2006; 73: 296-305• Calverley PMA, Nordyke RJ, Halbert RJ et al. Development of a population-based

screening questionnaire for COPD. J COPD 2005; 2: 225-232• van Schayck CP, Halbert RJ, Nordyke RJ et al. Comparison of existing symptom-

based questionnaires for identifying COPD in the general practice setting. Respirology 2005;10: 323-333

• David Price, Alan Crockett, Mats Arne, Bernard Garbe, Rupert Jones, Alan Kaplan, Arnulf Langhammer, Siân Williams, Barbara Yawn. DISCUSSION PAPER. Spirometry in primary care case-identification, diagnosis and management of COPD. Primary Care Respiratory Journal 2009; 18(3): 216-223

Page 46: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

• http://www.copdguidelines.ca/guidelines-lignes_e.php

• http://www.theipcrg.org/resources/ipcrg_copd_opinion_5.pdf

• http://www.thepcrj.org/journ/view_article.php?article_id=654

• WWW.THEIPCRG.ORG

• WWW.CCQ.NL

• www.ginastma.org

• www.copdgold.org

• https://fhs.umr.com/oss/export/sites/default/FiservHealthServices/SharedFiles/FH0060_Adult.pdf

• http://www.euro.who.int/document/e88698.pdf

• http://www.apa.org/pubs/videos/4310588-scale.aspx

• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2519083/

Page 47: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

DICTIONARY OF USED TERMS AND DEFINITIONS

Screening is the presumptive identification of unrecognized diseases or defects by the application of tests, examinations or other procedures which can be applied rapidly. Screening tests sort out apparently well persons who probably have a disease from those who probably do not. A screening test is not intended to be diagnostic. Persons with positive or suspicious findings must be referred to their physicians for diagnosis and necessary treatment.

Mass screening is the large scale screening of whole population groups.

Selective screening is screening in selected high-risk groups in a certain population. It can be large-scale.

Page 48: S creening for  COPD IN PHC WORKSHOP Vasiliki Garmiri Athanasios Symeonidis

Multiple (or multiphasic) screening is the application of two or more screening tests in combination to large groups of people.

 

Surveillance is a long-term process (close and continuous observation) similar to the application of screening examinations repeatedly at selected regular intervals of time. It is often used as a synonym of the word screening.

 

Case-finding is a form of screening aimed at detecting disease and bringing patients to treatment.

 

Population or epidemiological surveys are surveys that primarily aim at elucidating the prevalence, incidence and natural history of the variable/s under study rather than bringing patients to treatment (although case-finding is a by-product of surveys).

Early disease detection is the detection of disease at a primary stage by any means.